Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA)
Annual rept. 30 Mar 2006-29 Mar 2007
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
We propose to study the ability of quantitation of breast cancer tumor microvesicles MV to predict clinical outcomes in breast cancer patients. We also propose that treatment of HER2 breast cancer patients with trasutuzumab results in clearing of tumor MV from the blood. In order to achieve these aims, a precise and robust clinical assay is required. Flow cytometry, as originally proposed, and as used by numerous investigators, is inadequate for this task. Thus we have developed a novel bead capture procedure to isolate and analyze tumor MV from breast cancer patients. Anti-MUC1 coated beads are used to bind and isolate tumor MV from patient plasma. We have characterized these MUC-1 tumor MV and verified the specificity of the capture. The isolated tumor MV will be assayed by commercial ELISA for MUC1, tissue factor, MMPs, and uPA. We have an active IRB approved protocol and have begun to collect patient samples for this purpose.
- Medicine and Medical Research
- Plasma Physics and Magnetohydrodynamics